Semarion

#Cellular assays #High Throughput #Semarion

Semarion raises $3.8m to scale cell assay technology 

Semarion has raised $3.8 million to scale its next-generation cell assay technology and expand manufacturing of its microcarrier platform.  The company, a University of Cambridge spin-out from the Cambridge Laboratory, will use investment to facilitate commercial expansion and scale manufacturing of its SemaCyte platform, which enables adherent cell models to be handled as assay-ready,… Read More

#Business & Investment #News

Automated liquid handling
#Automation / robotics #Cellular assays #Collaboration #Drug discovery #Semarion #SPT Labtech

SPT Labtech and Semarion partner on automated cell-based discovery

SPT Labtech and Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, have announced a strategic collaboration.   The partnership will integrate SPT Labtech’s firefly liquid handling platform with Semarion’s SemaCyte microcarrier technology to develop an automated workflow to simplify and accelerate key stages of adherent cell assay development. … Read More

#Business & Investment #News

Scientist using a well plate
#Automated workflows #Cell culture #Drug discovery #In vitro assays #minit #Semarion

Early adopters get access to new microcarrier platform

Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, has opened the Early Adopter Programme for its SemaCyte Microcarrier Platform. The platform aims to overcome the limitations associated with adherent cell culture and assaying workflows by enabling small colonies of cells to be moved… Read More

#News